1 Study Matches
A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy, and Safety Study in Prurigo Nodularis with Nalbuphine ER Tables for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)
Prurigo Nodularis: Phase 2b/3 Subject and Investigator Blinded, 56 Week study. Oral medication taken twice daily, Males/Females 18 years and older with Prurigo Nodularis Prurigo Nodularis (PN) is a skin disease that causes hard, itchy lumps (nodules) to form on the skin. The itching (pruritus) can be intense, cause people to scratch themselves to the point of bleeding or pain. The goal of this study is to evaluate the change of itch with using Nalbuphine ER.
18 year(s) or older
Inclusion Criteria:PN involving 2 affected areas
Willing to follow all study directions and attend appointments
Exclusion Criteria:PN affecting only 1 part of the body
Certain diagnosis associated with PN are not allowed, coordinator will discuss specifics